| 07.27.22 | J&J's switch to subq Darzalex 85% complete; ARS inks merger to fund nasal spray EpiPen rival

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Webinar: The New Role of Social Networks in Patient Education

Thursday, August 4, 2022 | 2:00pm ET / 11:00am PT

Whether developing a drug for a new indication, preparing for the launch of a new drug, or building awareness of an existing therapy, one thing is clear; you have to break through the noise and engage patients directly at every stage of the process to be successful. Join this webinar for insights into the increasingly important role social networks play in patient education and engagement. Register now.

Today's Rundown

J&J's switch from IV to subcutaneous Darzalex is 85% complete in the US As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray Avadel gets tentative FDA nod for rival to Jazz narcolepsy drug Large-scale screen shows how cancer cells respond to drug delivery nanoparticles Pfizer, BioNTech rebuff CureVac's 'groundless' patent infringement claims against COVID-19 shot Comirnaty 'The Top Line' podcast: Biotech layoffs trend up, the pandemic's impact on generic drug sales, plus this week's headlines

Featured Story

J&J's switch from IV to subcutaneous Darzalex is 85% complete in the US

By Nick Paul Taylor

Johnson & Johnson’s attempt to switch physicians from intravenous to subcutaneous Darzalex is almost complete. Having won FDA approval for Darzalex Faspro in May 2020, J&J has converted 85% of its U.S. business to the subcutaneous formulation of the cancer treatment.

Webinar: GeneTox: A Pivotal Part of Safety Assessment

Wednesday, August 17, 2022 | 11am ET / 8am PT

This webinar will highlight the standard battery and the follow up assays, and the approaches for selection of these assays. Frontage Laboratories offer standard battery of GeneTox assays, and our experts can guide our clients for the follow up assays, if and when needed. Register now.

As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray

By Nick Paul Taylor

ARS Pharmaceuticals is backing onto Nasdaq through a reverse merger with Silverback Therapeutics to bag cash to commercialize an epinephrine nasal spray and win market share from the incumbent EpiPen.

Avadel gets tentative FDA nod for rival to Jazz narcolepsy drug

By Nick Paul Taylor

Avadel Pharmaceuticals has taken a step toward challenging Jazz Pharmaceuticals for the narcolepsy market. The FDA granted tentative approval to the company’s extended-release rival to Xyrem, leaving a patent as the last barrier between it and the market.

Large-scale screen shows how cancer cells respond to drug delivery nanoparticles

By Nick Paul Taylor

What factors determine the effectiveness of drug delivery nanoparticles in different settings? The lack of a good way to answer that question has potentially held back a technology with the potential to improve the risk-benefit profile of cancer therapies. Recognizing that, researchers at Massachusetts Institute of Technology have run a large-scale screen to show how cancer cells respond to nanoparticles.

Pfizer, BioNTech rebuff CureVac's 'groundless' patent infringement claims against COVID-19 shot Comirnaty

By Fraiser Kansteiner

After developing the massively successful COVID shot, Comirnaty, Pfizer and BioNTech are responding to CureVac's litigation, saying they are facing what they call “threats of a groundless patent infringement suit by a company, CureVac, who has been unable to bring to market any product to help in the fight against COVID-19.”

'The Top Line' podcast: Biotech layoffs trend up, the pandemic's impact on generic drug sales, plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss the significant increase in layoffs and what that means for the biotech industry. Also under discussion is our special report on the top 10 companies by generic drugs sales.

Article Download: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

The costs of drug development have escalated greatly in recent years. Read the article with expert insights on how to address compounds with difficult physicochemical properties and unfavorable absorption characteristics early on in the development process to reduce costs and attrition rates. Download now.